FDA
-
-
-
-
-
-
-
Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular Dysfunction
-
-
-
-
-
-
-
Caladrius Biosciences Reports Second Quarter 2021 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Caladrius Biosciences to Present at Noble Capital Markets Virtual Investor Forum during the 16th Annual World Stem Cell Summit
-
-
-
-
-
-
-
Caladrius Biosciences Reports First Quarter 2021 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Caladrius Biosciences Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease
-
-
-
-
-
-
-
Caladrius Biosciences, Inc. Closes $65 Million Registered Direct Offerings Priced At-The-Market under Nasdaq Rules
-
-
-
-
-
-
-
Caladrius Biosciences Announces Participation in Upcoming Virtual Conferences in February 2021
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

